Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR

Immunity

Volumn 22, Issue 1, 2005, Pages 117-129

  Kuball, Jürgen ^a   Schmitz, Frank W ^a   Voss, Ralf Holger ^a   Ferreira, Edite Antunes ^a   Engel, Renate ^a   Guillaume, Philippe ^b   Strand, Susanne ^a   Romero, Pedro ^b   Huber, Christoph ^a   Sherman, Linda A ^c   Theobald, Matthias ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; HLA A2 ANTIGEN; HLA A2.1 ANTIGEN; PROTEIN P53; T LYMPHOCYTE RECEPTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CELL ACTIVITY; CELL INTERACTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HELPER CELL; HUMAN; HUMAN CELL; MOLECULE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RETROVIRUS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE; TUMOR;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CLONING, MOLECULAR; FLOW CYTOMETRY; HUMANS; MICE; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 19944434233     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immuni.2004.12.005     Document Type: Article

References (53)

1. Ashcroft M., Vousden K.H. Regulation of p53 stability. Oncogene. 18:1999;7637-7643
2. Bennett S.R., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F., Heath W.R. Help for cytotoxic T-cell responses is mediated by CD40 signalling. Nature. 398:1998;478-480
3. Berger C., Huang M.-L., Gough M., Greenberg P.D., Riddell S.R., Kiem H.-P. Nonmyeloablative immunosuppressive regimen prolongs in vivo persistence of gene-modified autologous T cells in a nonhuman primate model. J. Virol. 75:2001;799-808
4. Berger C., Blau C.A., Huang M.-L., Iuliucci J.D., Dalgarno D.C., Gaschet J., Heimfeld S., Clackson T., Riddell S.R. Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood. 103:2004;1261-1269
5. Buslepp J., Wang H., Biddison W.E., Appella E., Collins E.J. A correlation between TCR Vα docking on MHC and CD8 dependence. implications for T cell selection Immunity. 19:2003;595-606
6. Card K.F., Price-Schiavi S.A., Liu B., Thomson E., Nieves E., Belmont H., Builes J., Jiao J., Hernandez J., Weidanz J., et al. A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity. Cancer Immunol. Immunother. 53:2004;345-357
7. Cawthon A.G., Alexander-Miller M.A. Optimal colocalization of TCR and CD8 as a novel mechanism for the control of functional avidity. J. Immunol. 169:2002;3492-3498
8. Chamoto K., Tsuji T., Funamoto H., Kosaka A., Matsuzaki J., Sato T., Abe H., Fujio K., Yamamoto K., Kitamura T., et al. Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res. 64:2004;386-390
9. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifio N.P., Hubicki A.M., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:2002;850-854
10. Freedman D.A., Levine A.J. Regulation of the p53 protein by the MDM2 oncoprotein - thirty-eighth G.H.A. Clowes memorial award lecture. Cancer Res. 59:1999;1-7
11. Gill R.G., Lafferty K.J. A quantitative analysis of lymphokine release from activated T cells. evidence for a novel form of T-T collaboration in vitro J. Immunol. 143:1989;4009-4014
12. Gotter J., Brors B., Hergenhahn M., Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J. Exp. Med. 199:2004;155-166
13. Heemskerk M.H., Hoogeboom M., de Paus R.A., Kester M.G., van der Hoorn M.A., Goulmy E., Willemze R., Falkenburg J.H. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood. 102:2003;3530-3540
14. Heemskerk M.H., Hoogeboom M., Hagedoorn R., Kester M.G., Willemze R., Falkenburg J.H. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J. Exp. Med. 199:2004;885-894
15. + T cells. it may get by with a little help from its friends J. Clin. Invest. 110:2002;1415-1417
16. Holler P.D., Kranz D.M. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity. 18:2003;255-264
17. Holler P.D., Holman P.O., Shusta E.V., O'Herrin S., Wittrup K.D., Kranz D.M. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc. Natl. Acad. Sci. USA. 97:2000;5387-5392
18. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49-53
19. Holmberg K., Mariathasan S., Ohteki T., Ohashi P.S., Gascoigne N.R. TCR binding kinetics measured with MHC class I tetramers reveal a positive selecting peptide with relatively high affinity for TCR. J. Immunol. 171:2003;2427-2434
20. + T cells in the antitumor immune response. J. Exp. Med. 188:1998;2357-2368
21. + T lymphocytes. Nature. 421:2003;852-856
22. Kessels H.W., van den Boom M.D., Spits H., Hooijberg E., Schumacher T.N. Changing T cell specificity by retroviral T cell receptor display. Proc. Natl. Acad. Sci. USA. 97:2000;14578-14583
23. Kessels H.W., Wolkers M.C., van den Boom M.D., van der Valk M.A., Schumacher T.N. Immunotherapy through TCR gene transfer. Nat. Immunol. 2:2001;957-961
24. Kuball J., Schuler M., Antunes Ferreira E., Herr W., Neumann M., Obenauer-Kutner L., Westreich L., Huber C., Wolfel T., Theobald M. Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Gene Ther. 9:2002;833-843
25. Kuckelkorn U., Ferreira E.A., Drung I., Liewer U., Kloetzel P.M., Theobald M. The effect of the interferon-γ-inducible processing machinery on the generation of a naturally tumor-associated human cytotoxic T lymphocyte epitope within a wild-type and mutant p53 sequence context. Eur. J. Immunol. 32:2002;1368-1375
26. Kurose K., Gilley K., Matsumoto S., Watson P.H., Zhou X.-P., Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat. Genet. 32:2002;355-357
27. Lotz C., Ferreira E.A., Drexler I., Mutallib S.A., Huber C., Sutter G., Theobald M. Partial tyrosinase-specific self tolerance by HLA-A*0201- restricted cytotoxic T lymphocytes in mice and man. Int. J. Cancer. 108:2004;571-579
28. Luznik L., Jalla S., Engstrom L.W., Iannone R., Fuchs E.J. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 98:2001;3456-3464
29. Melief C.J., Toes R.E., Medema J.P., van der Burg S.H., Ossendorp F., Offringa R. Strategies for immunotherapy of cancer. Adv. Immunol. 75:2000;235-282
30. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ Proc. Natl. Acad. Sci. USA. 96:1999;8633-8638
31. Ossendorp F., Mengedé E., Camps M., Filius R., Melief C.J. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187:1998;693-702
32. + T cell responses in antitumor immunity. Curr. Opin. Immunol. 10:1998;588-594
33. Pittet M.J., Rubio-Godoy V., Bioley G., Guillaume P., Batard P., Speiser D., Luescher I., Cerottini J.-C., Romero P., Zippelius A. α3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. J. Immunol. 171:2003;1844-1849
34. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells. Immunity. 12:2000;677-686
35. + T-helper cell and a T-killer cell. Nature. 393:1998;474-478
36. Romero P., Dunbar P.R., Valmori D., Pittet M., Ogg G.S., Rimoldi D., Chen J.-L., Liénard D., Cerottini J.-C., Cerundolo V. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytoloytic T lymphocytes. J. Exp. Med. 188:1998;1641-1650
37. Roszkowski J.J., Yu D.C., Rubinstein M.P., McKee M.D., Cole D.J., Nishimura M.I. CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell. J. Immunol. 170:2003;2582-2589
38. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., Posati S., Rogaia D., Frassoni F., Aversa F., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 295:2002;2097-2100
39. Savage P.A., Boniface J.J., Davis M.M. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity. 10:1999;485-492
40. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 393:1998;480-483
41. Sherman L.A., Hesse S.V., Irwin M.J., LaFace D., Peterson P. Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. Science. 258:1992;815-818
42. Snijders A., Kalinski P., Hilkens C.M., Kapsenberg M.L. High-level IL-12 production by human dendritic cells requires two signals. Int. Immunol. 10:1998;1593-1598
43. Stanislawski T., Voss R.H., Lotz C., Sadovnikova E., Willemsen R.A., Kuball J., Ruppert T., Bolhuis R.L., Melief C.J., Huber C., et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2:2001;962-970
44. Stauss H.J. Immunotherapy with CTLs restricted by nonself MHC. Immunol. Today. 20:1998;193-200
45. + T cells after acute infection. Nat. Immunol. 5:2004;927-933
46. Theobald M., Biggs J., Dittmer D., Levine A.J., Sherman L.A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA. 92:1995;11993-11997
47. Theobald M., Biggs J., Hernandez J., Lustgarten J., Labadie C., Sherman L.A. Tolerance to p53 by A2.1-restricted T lymphocytes. J. Exp. Med. 185:1997;833-841
48. Theobald M., Ruppert T., Kuckelkorn U., Hernandez J., Häussler A., Ferreira E.A., Liewer U., Biggs J., Levine A.J., Huber C., et al. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J. Exp. Med. 188:1998;1017-1028
49. + T cells and their role in antitumor immune responses. J. Exp. Med. 189:1999;753-756
50. Vierboom M.P., Nijman H.W., Offringa R., van der Voort E.I., van Hall T., van den Broek L., Fleuren G.J., Kenemans P., Kast W.M., Melief C.J. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 186:1997;695-704
51. Vierboom M.P., Zwaveling S., Bos G.M., Ooms M., Krietemeijer G.M., Melief C.J., Offringa R. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lmphocytes. Cancer Res. 60:2000;5508-5513
52. Wroblewski V.J., Witcher D.R., Becker G.W., Davis K.A., Dou S., Micanovic R., Newton C.M., Noblitt T.W., Richardson J.N., Song H.Y., et al. Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT. Biochem. Pharmacol. 65:2003;657-667
53. + T-helper cells. Cancer Res. 62:2002;6187-6193